A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States
Abstract Background Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patients initiating fremanezumab therapy. Methods Data were obtained for this...
Main Authors: | Lynda J. Krasenbaum, Vasantha L. Pedarla, Stephen F. Thompson, Krishna Tangirala, Joshua M. Cohen, Maurice T. Driessen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-05-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | https://doi.org/10.1186/s10194-022-01413-z |
Similar Items
-
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
by: Peter McAllister, et al.
Published: (2021-12-01) -
Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
by: Seiya Ohtani, et al.
Published: (2023-11-01) -
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
by: Maurice T. Driessen, et al.
Published: (2022-05-01) -
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
by: Maurice T. Driessen, et al.
Published: (2022-04-01) -
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
by: Stephanie J. Nahas, et al.
Published: (2021-11-01)